7 RESULTS
COMMENT Subhojit Roy and his team report exciting transgenic-mouse work, targeting the amyloid precursor protein (APP) with CRISPR-Cas9/AAV. This follows nicely on Dr. Roy’s cell-based work and provides promising, preliminary evidence for using this approach to t
COMMENT This is nice work and is generally supportive of what we know about these biomarkers: At the asymptomatic stage, fluid biomarkers of p-tau are the most dynamic and therefore had the strongest association with early regional tau PET change in the temporal
COMMENT The authors provide important findings that may help to answer some current uncertainties, as well as guide future consideration of this or a similar class of compounds: Mechanism-based versus compound-based. Although both compounds share similarities, th
COMMENT This study by Janelidze et al. is a timely contribution to the field of tau-related AD diagnostics. This study highlights the value of using newer diagnostic platforms to explore additional phosphorylation sites in the CSF of AD. By assessing the associat
COMMENT Quiroz and colleagues provide the first report of AV1451 tau-PET in a cohort of at risk for autosomal-dominant Alzheimer's disease (ADAD) related to the PSEN1 E280A mutation. By studying mutation carriers at various stages of the disease cascade (amy
COMMENT The report provides an interesting approach using a heterozygous-dominant disease, and provides some clear translatability to many ADAD mutations. However, the mutation that was the focus of this research was a deletion, and most ADAD-causing mutations ar
COMMENT The association of seizures and epilepsy with Alzheimer’s disease (AD) is well established. However, there is increasing recognition that seizures may occur in milder stages of the disease (Vossel et al., 2016; Zarea et al., 2016), and that this may be a
